SCHEDULE: Lifecore Biomedical Agrees to Merger Deal

Lifecore Biomedical, Inc. has entered into a merger agreement with Lifecore Inc. and Hazel Merger Sub, Inc., with shareholders to receive $6.28 cash plus a contingent value right per share.

Summary

• Lifecore Biomedical, Inc. has entered into an Agreement and Plan of Merger with Lifecore Inc. and its subsidiary Hazel Merger Sub, Inc.
• The merger will result in Lifecore Biomedical becoming a wholly owned subsidiary of Lifecore Inc.
• Each outstanding share of common stock will receive $6.28 in cash and one contingent value right (CVR) per share.
• Series A Preferred Stock will also be converted into cash and a CVR based on its conversion amount.
• The transaction is subject to customary closing conditions, including adoption by Lifecore stockholders and antitrust approvals.
• Legion Partners and its affiliates, holding approximately 17.3% of the outstanding shares, have entered into a voting and support agreement to vote in favor of the merger.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the merger agreement offers a clear cash and CVR payout to shareholders, indicating a definitive exit strategy.

Positives

• Shareholders will receive a definitive cash payout of $6.28 per share, plus a contingent value right, providing a clear return on investment.
• The merger agreement provides a clear exit strategy for shareholders.
• Legion Partners, a significant shareholder group, has agreed to support the merger, increasing the likelihood of its approval.
• The transaction is structured to provide value for both common and Series A Preferred Stock holders.

Negatives

• The filing does not detail the specific terms or potential value of the contingent value right (CVR), leaving some uncertainty about the total potential payout.
• The merger is subject to closing conditions, including regulatory approvals and stockholder adoption, which could potentially delay or prevent completion.

Risks

• The merger is contingent upon the adoption of the Merger Agreement by Lifecore stockholders.
• Completion of the merger is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
• There is a risk that other governmental consents, registrations, or approvals may not be obtained.
• A legal restraint could prohibit or make the consummation of the merger illegal.

Future Outlook

The primary future outlook is the completion of the merger, which is subject to customary closing conditions including stockholder approval and regulatory review. Upon completion, Lifecore Biomedical will become a wholly owned subsidiary of Lifecore Inc., and shareholders will receive $6.28 in cash and one CVR per share.

Management Comments

• Mr. Kiper has been awarded certain restricted stock units ('RSUs') in connection with his service as a director of the Issuer.
• Because Mr. Kiper serves on the Board as a representative of Legion Partners Asset Management and the Reporting Persons, he does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position.
• As a result, when the Issuer delivered such RSUs to Mr. Kiper, Legion Partners Asset Management was entitled to receive all of the economic interests in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position, for no consideration.

Industry Context

StockSavvy.ai notes that the announcement of a merger agreement is a significant event for a company in the biomedical sector, often signaling a strategic shift or an attractive valuation by an acquirer. The inclusion of a contingent value right suggests that the acquirer sees potential for future value creation that they wish to share with existing shareholders.

Corporate Governance

Related Party Transactions

• Christopher S. Kiper, as a director, was awarded RSUs. However, the economic interest in these RSUs was transferred to Legion Partners Asset Management for no consideration, as Mr. Kiper serves as a representative of Legion Partners.
• Legion Partners Asset Management, LLC is the investment advisor for Legion Partners I and II.
• Legion Partners Holdings, LLC is the sole member of Legion Partners Asset Management and the sole member of Legion Partners, LLC.

Stakeholder Impact

• Shareholders: Will receive $6.28 in cash and one CVR per share, providing a clear exit and potential upside.
• Creditors: The merger may impact existing debt obligations, though details are not provided.
• Employees: The acquisition by a new parent company could lead to changes in employment terms, benefits, or organizational structure.

Next Steps

• Lifecore Biomedical stockholders will vote on the adoption of the Merger Agreement.
• The parties will seek expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
• Obtain other required governmental consents, registrations, or approvals.
• Complete the merger upon satisfaction of all closing conditions.

Key Dates

Recommendation

The merger offers a clear cash payout, which is positive. However, the value of the CVR is uncertain, and the deal is subject to closing conditions. A 'hold' recommendation reflects the certainty of the cash component while acknowledging the contingent upside and potential deal risks.

Keywords

Merger Agreement, Lifecore Biomedical, Lifecore Inc., Hazel Merger Sub, Contingent Value Right, Series A Preferred Stock, Voting Agreement, Antitrust Approval